Distinct gastric phenotype in patients with pathogenic variants in SMAD4: A nationwide cross-sectional study

Abstract

Background and study aims In most patients with juvenile polyposis Syndrome, it is possible to detect a pathogenic germline variant in SMAD4 or BMPR1A. It is well known that patients with a pathogenic variant in SMAD4 have a higher risk of gastric polyposis and gastric cancer compared to BMPR1A carriers, but the natural history of gastric involvement is poorly described. We aimed to systematically review endoscopic and histopathological gastric findings in Danish patients with pathogenic variants in SMAD4.

Patients and methods This was a retrospective, cross-sectional study including endoscopic and histological gastric findings in all known Danish patients with pathogenic variants in SMAD4. The patients were identified by data from various registries as well as from clinical genetic departments and laboratories.

Results We identified 41 patients (2–72 years) with a pathogenic SMAD4 variant. In 31 patients, we were able to retrieve information on upper gastrointestinal endoscopy. Eighty-seven percent had at least one gastric abnormality including erythema (72 %) and edema (72 %). Half of the patients also had vulnerability of the mucosa and 68 % had gastric polyposis. An increasing frequency of abnormalities were observed with increasing age. Gastric cancer was diagnosed in 5 % of the cases and 22 % had a gastrectomy mainly because of massive polyposis.

Conclusions This study showed that most patients with pathogenic SMAD4 variants have a distinct phenotype of the gastric mucosa, and with an increasing severity in the elderly patients. These findings provide new insights into the natural history of gastric manifestations in patients with pathogenic SMAD4 variants.

Publikationsverlauf

Eingereicht: 30. Mai 2022

Angenommen nach Revision: 30. September 2022

Accepted Manuscript online:
30. September 2022

Artikel online veröffentlicht:
15. Dezember 2022

• References

• 1 Gallione CJ, Repetto GM, Legius E. et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004; 363: 852-859
• 2 Teekakirikul P, Milewicz DM, Miller DT. et al. Thoracic aortic disease in two patients with juvenile polyposis syndrome and SMAD4 mutations. Am J Med Genet A 2013; 161A: 185-191
• 3 Blatter R, Tschupp B, Aretz S. et al. Disease expression in juvenile polyposis syndrome: a retrospective survey on a cohort of 221 European patients and comparison with a literature-derived cohort of 473 SMAD4/BMPR1A pathogenic variant carriers. Genet Med 2020; 22: 1524-1532
• 4 Friedl W, Uhlhaas S, Schulmann K. et al. Juvenile polyposis: massive gastric polyposis is more common in MADH4 mutation carriers than in BMPR1A mutation carriers. Hum Genet 2002; 111: 108-111
• 5 Handra-Luca A, Condroyer C, de Moncuit C. et al. Vesselsʼ morphology in SMAD4 and BMPR1A-related juvenile polyposis. Am J Med Genet A 2005; 138A: 113-117
• 6 Richards S, Aziz N, Bale S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405-424
• 7 Karstensen JG, Bülow S, Burisch J. et al. Validation of the endoscopic part of the spigelman classification for evaluating duodenal adenomatosis in familial adenomatous polyposis: a prospective study of interrater and intrarater reliability. Am J Gastroenterol 2022; 117: 343-345
• 8 Spigelman AD, Williams CB, Talbot IC. et al. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 1989; 2: 783-785
• 9 Jelsig AM, Karstensen JG, Jespersen N. et al. Danish guidelines for management of non-APC-associated hereditary polyposis syndromes. Hered Cancer Clin Pract 2021; 19: 41
• 10 Aretz S, Stienen D, Uhlhaas S. et al. High proportion of large genomic deletions and a genotype phenotype update in 80 unrelated families with juvenile polyposis syndrome. J Med Genet 2007; 44: 702-709
• 11 O'Malley M, LaGuardia L, Kalady MF. et al. The prevalence of hereditary hemorrhagic telangiectasia in juvenile polyposis syndrome. Dis Colon Rectum 2012; 55: 886-892
• 12 Howe JR, Mitros FA, Summers RW. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol 1998; 5: 751-756
• 13 Bianchi LK, Burke CA, Bennett AE. et al. Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2008; 6: 180-185
• 14 Li J, Woods SL, Healey S. et al. Point mutations in Exon 1b of apc reveal gastric adenocarcinoma and proximal polyposis of the stomach as a familial adenomatous polyposis variant. Am J Hum Genet 2016; 98: 830-842
• 15 Miyazawa K, Shinozaki M, Hara T. et al. Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells 2002; 7: 1191-1204
• 16 Woodford-Richens K, Williamson J, Bevan S. et al. Allelic loss at SMAD4 in polyps from juvenile polyposis patients and use of fluorescence in situ hybridization to demonstrate clonal origin of the epithelium. Cancer Res 2000; 60: 2477-2482
• 17 Woodford-Richens K, Bevan S, Churchman M. et al. Analysis of genetic and phenotypic heterogeneity in juvenile polyposis. Gut 2000; 46: 656-660
• 18 Langeveld D, van Hattem WA, de Leng WW. et al. SMAD4 immunohistochemistry reflects genetic status in juvenile polyposis syndrome. Clin Cancer Res 2010; 16: 4126-4134